Sun Xuedong, Han Yanjing, Wang Qi, Su Tianhao, Hu Yuefeng, Wei Jian, Zhang Zhiyuan, Yang Siwei, Jin Long
Department of Interventional Radiology, Beijing Friendship Hospital, Capital Medical University, Beijing, People's Republic of China.
J Thorac Imaging. 2025 Sep 1;40(5):e0829. doi: 10.1097/RTI.0000000000000829.
Bronchial arterial chemoembolization (BACE), as a safe and effective minimally invasive treatment method, is increasingly being accepted by more and more patients with advanced nonsmall-cell lung cancer (NSCLC). In recent years, drug-eluting beads (DEB)-BACE has also been applied in the field of lung cancer. It is still unclear which is more recommended due to the limited number of comparative studies between conventional BACE (C-BACE) and DEB-BACE.
To compare the safety and efficacy of C-BACE (BACE with gelfoam particles) and DEB-BACE for advanced NSCLC.
From January 2021 to April 2023, 48 consecutive patients (37 males and 11 females) with advanced NSCLC treated with DEB-BACE (group A) or C-BACE (group B) at our center were collected retrospectively in this study. There were 18 patients in group A and 30 patients in group B. The technical success rate, adverse events, objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), and overall survival (OS) were compared between the 2 groups.
The technical success rate in both groups was 100%. The median OS times were 19.5 months and 12.5 months in group A and group B, respectively ( P =0.0062). The median PFS times were 13 months and 7 months in group A and group B, respectively ( P =0.0072). The ORRs at 6 months were 72.2% and 46.7% in group A and group B, respectively ( P =0.084). The DCRs at 6 months were 88.9% and 63.3% in group A and group B, respectively ( P =0.043). Grade 1 adverse events like chest pain, and cough were common, while serious adverse events did not occur.
BACE with DEB or gelfoam particles were equally safe. The DEB-BACE showed better survival and tumor response than C-BACE for advanced NSCLC.
支气管动脉化疗栓塞术（BACE）作为一种安全有效的微创治疗方法，越来越被晚期非小细胞肺癌（NSCLC）患者所接受。近年来，载药微球（DEB）-BACE也已应用于肺癌领域。由于传统BACE（C-BACE）与DEB-BACE之间的对比研究数量有限，哪种方法更值得推荐仍不明确。
比较C-BACE（使用明胶海绵颗粒的BACE）和DEB-BACE治疗晚期NSCLC的安全性和疗效。
本研究回顾性收集了2021年1月至2023年4月在我院中心接受DEB-BACE（A组）或C-BACE（B组）治疗的48例连续晚期NSCLC患者（男性37例，女性11例）。A组18例，B组30例。比较两组的技术成功率、不良事件、客观缓解率（ORR）、疾病控制率（DCR）、无进展生存期（PFS）和总生存期（OS）。
两组技术成功率均为100%。A组和B组的中位OS时间分别为19.5个月和12.5个月（P = 0.0062）。A组和B组的中位PFS时间分别为13个月和7个月（P = 0.0072）。A组和B组6个月时的ORR分别为72.2%和46.7%（P = 0.084）。A组和B组6个月时的DCR分别为88.9%和63.3%（P = 0.043）。胸痛、咳嗽等1级不良事件常见，未发生严重不良事件。
DEB或明胶海绵颗粒的BACE同样安全。对于晚期NSCLC，DEB-BACE在生存期和肿瘤反应方面优于C-BACE。
